In vivo anti-hyperuricemic and xanthine oxidase inhibitory properties of tuna protein hydrolysates and its isolated fractions

被引:99
作者
He, Weiwei [1 ]
Su, Guowan [1 ]
Sun-Waterhouse, Dongxiao [1 ,2 ]
Waterhouse, Geoffrey I. N. [1 ,2 ]
Zhao, Mouming [1 ]
Liu, Yang [1 ]
机构
[1] South China Univ Technol, Sch Food Sci & Engn, Guangzhou 510640, Guangdong, Peoples R China
[2] Univ Auckland, Sch Chem Sci, Private Bag 92019, Auckland, New Zealand
关键词
Hyperuricemic mice; Xanthine oxidase inhibition; Structure-activity relationship; Di-/tri-peptide; Molecular docking; URIC-ACID; PROTEOLYTIC DIGEST; SHARK CARTILAGE; DIPEPTIDES; PEPTIDES; RATS; DISORDERS; INGESTION; EXTRACT; DOCKING;
D O I
10.1016/j.foodchem.2018.08.057
中图分类号
O69 [应用化学];
学科分类号
070301 [无机化学];
摘要
This study follows recent attempts to discover natural xanthine oxidase (XO) inhibitors from foods, focusing herein on under-researched fish proteins. The anti-hyperuricemic function of tuna flesh hydrolysate (TPH) produced using Alcalase 2.4L was confirmed in potassium oxonate-induced hyperuricemic rats. TPH was separated using 80 wt% aqueous ethanol. The ethanol-soluble fraction (ESF) abundant in small peptides (< 1000 Da) afforded the highest XO inhibition. Separation of ESF by Sephadex G-15 and UPLC/MS/MS revealed 13 di-/tri-peptides (12 are newly identified XO inhibitors). Their XO inhibitory activities were assessed using corresponding synthetic peptides via an improved HPLC method. Results indicate that Phe-containing peptides were more potent XO inhibitors than Trp-containing peptides, with Phe-His having the highest XO inhibitory activity (IC50 = 25.7 mM). Molecular docking studies revealed the importance of two hydrogen bonds and one pi-pi stacking interaction with Phe-914 in XO for XO-peptide inhibitor binding. Phe-containing di-/tripeptides could be potent XO inhibitors against hyperuricemia.
引用
收藏
页码:453 / 461
页数:9
相关论文
共 37 条
[1]
Effect of Allopurinol on Blood Pressure: A Systematic Review and Meta-Analysis [J].
Agarwal, Vikram ;
Hans, Nidhi ;
Messerli, Franz H. .
JOURNAL OF CLINICAL HYPERTENSION, 2013, 15 (06) :435-442
[2]
BURKE A., 2006, Goodman Gilman's the Pharmaceutical Basis of Therapeutics, P671
[3]
Latest evidence on gout management: what the clinician needs to know [J].
Burns, Christopher M. ;
Wortmann, Robert L. .
THERAPEUTIC ADVANCES IN CHRONIC DISEASE, 2012, 3 (06) :271-286
[4]
X-ray Crystal Structure of a Xanthine Oxidase Complex with the Flavonoid Inhibitor Quercetin [J].
Cao, Hongnan ;
Pauff, James M. ;
Hille, Russ .
JOURNAL OF NATURAL PRODUCTS, 2014, 77 (07) :1693-1699
[5]
XANTHINE-OXIDASE AS A SOURCE OF FREE-RADICAL DAMAGE IN MYOCARDIAL ISCHEMIA [J].
CHAMBERS, DE ;
PARKS, DA ;
PATTERSON, G ;
ROY, R ;
MCCORD, JM ;
YOSHIDA, S ;
PARMLEY, LF ;
DOWNEY, JM .
JOURNAL OF MOLECULAR AND CELLULAR CARDIOLOGY, 1985, 17 (02) :145-152
[6]
Uric Acid - Key Ingredient in the Recipe for Cardiorenal Metabolic Syndrome [J].
Chaudhary, Kunal ;
Malhotra, Kunal ;
Sowers, James ;
Aroor, Annayya .
CARDIORENAL MEDICINE, 2013, 3 (03) :208-220
[7]
Fibril aggregation inhibitory activity of the β-sheet breaker peptides: a molecular docking approach [J].
Chini, Maria Giovanna ;
Scrima, Mario ;
D'Ursi, Anna Maria ;
Bifulco, Giuseppe .
JOURNAL OF PEPTIDE SCIENCE, 2009, 15 (03) :229-234
[8]
Davidoff A, 2016, Xanthine oxidase inhibitor formulations, Patent No. [US20160038595A1, 20160038595]
[9]
Mechanisms underlying the xanthine oxidase inhibitory effects of dietary flavonoids galangin and pinobanksin [J].
Dong, Yi ;
Huang, Huihua ;
Zhao, Mouming ;
Sun-Waterhouse, Dongxiao ;
Lin, Lianzhu ;
Xiao, Chuqiao .
JOURNAL OF FUNCTIONAL FOODS, 2016, 24 :26-36
[10]
The role of hyperuricemia in vascular disorders [J].
Edwards, N. Lawrence .
CURRENT OPINION IN RHEUMATOLOGY, 2009, 21 (02) :132-137